Divisions of Neurosurgery Neuro-Oncology, Department of Surgery, Sherbrooke University and Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada Abstract Malignant astrocytomas are aggressive neoplasms with a dismal prognosis despite optimal treatment. Maximal resective surgery is traditionally complemented by radiation therapy. Chemotherapy is now used on patients as initial therapy when their functional status is congruent with further treatment. The classic agents used are nitrosoureas, but temozolomide has taken the front seat recently, with recent data demonstrating increased survival when this agent is used concurrently with radiation therapy in newly diagnosed glioblastoma patients. A new class of agents, refered to as biological modifiers, are increasingly used in clinical trials in an effort to affect the intrinsic biologic aberrations harboured by tumor cells. These drugs comprise differentiation agents, anti-angiogenic agents, matrixmetalloproteinase inhibitors and signal transduction inhibitors, among others. This article reviews the standard cytotoxic agents that have been used to treat malignant astrocytomas, and the different combination regimens offering promise. In addition, recent advances with biological modifiers are also discussed. Three major histological types of diffuse infiltrative tumors are recognized by the World Health Organization's classification of gliomas: astrocytoma, oligodendrogliomas, and oligoastrocytomas.1 These tumors are further classified by subtypes mainly for astrocytomas ; and by histological grading. Grading usually serves the purpose of orienting treatment and predicting in the most accurate way the outcome for a given patient. Glial neoplasms represent a continuum of increasingly cellular and pleiomorphic lesions.1-3 Therefore grading systems translate a punctual assessment of this continuum, and can only approximate the biological behavior of a tumor. For astrocytic tumors, a four tier system is used.3, 4 The term malignant astrocytoma typically refers to grade III and IV fibrillary astrocytomas, respectively dubbed anaplastic astrocytoma AA ; and glioblastoma multiforme GBM ; . Malignant astrocytomas constitute about 50% to 60% of primary brain tumors, with an incidence ranging from 5 to 8 per 100, 000 inhabitants.5 Peak incidence is in the fifth or sixth decade of life, and has been increasing in recent years, an observation that may not be fully explained by aging of the population.6 In adults, malignant astrocytomas are almost exclusively supratentorial in location over 90% ; . These tumors spread by diffusely infiltrating the brain, and tumor cells are found at a distance from the enhancing anomalies on radiological studies.7 This fact accounts in part for their dismal prognosis, by preventing a complete resection and rendering local treatment modalities only partially effective. Standard treatment for astrocytic tumors has traditionally consisted of maximal surgical resection, followed by radiotherapy. The most frequently used radiation dose-schedule consists of 60 Gy given in 30 fractions over six weeks. Even with this so-called optimal treatment, a cure cannot be considered an accessible goal. The median survival produced by this approach is only 35 to 48 weeks for patients bearing a GBM.8, 9 Anaplastic astrocytoma patients fare better, with a median survival of two to three years, This review article appeared originally in Can J Neurol Sci 2006; 33: 127-40. The article is reproduced with kind permission from the Journal under the special arrangement of "Journal Article Exchange" between Canadian Journal of Neurosciences and Neurology Asia.
EXHIBIT A FORM OF NOTICE OF EXERCISE OF OPTION Date NovaDel Pharma Inc. Attention: Board of Directors NovaDel Pharma Inc. Purchase of Option Shares Gentlemen: In accordance with the Stock Option Agreement dated as of January 17, 2006 "Agreement" ; between THOMAS E. BONNEY "Optionee" ; and NovaDel Pharma Inc. the "Company" ; , the Optionee hereby irrevocably elects to exercise the right to purchase shares of the Company's common stock, par value $.001 per share "Common Stock" ; , which are being purchased for investment and not for resale. All capitalized terms not defined herein shall have the meanings ascribed to them in the Plan. As payment for my shares, enclosed is check and complete applicable boxes ; : a certified check ; bank check ; payable to the order of "NovaDel Pharma Inc." in the sum of $ confirmation of wire transfer in the amount of $ and or The Optionee hereby represents, warrants to, and agrees with, the Company that i ; The Optionee is acquiring the Option Shares for his own account for investment purposes only and not with a view to, or for the resale in connection with any "distribution" thereof for purposes of the Securities Act of 1933 the "1933 Act" ii ; The Optionee is aware of the Company's business affairs and financial condition, and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the securities. The Optionee has received a copy of all reports and documents required to be filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934 "Exchange Act" ; within the last 24 months and all reports issued by the Company to its stockholders; iii ; The Optionee understands that he must bear for an indefinite period of time the economic risk of an investment in the Option Shares, which cannot be sold by him unless they are registered under the 1933 Act or an exemption therefrom is available thereunder and that the Company is under no obligation to register the Option Shares for sale under the 1933 Act; iv ; In his position with the Company, the Optionee has had both the opportunity to ask questions and receive answers from the officers and directors of the Company and all persons acting on its behalf concerning the terms and conditions of the offer made hereunder and to obtain any additional information to the extent the Company possess or may possess such information or can acquire it without unreasonable effort or expense necessary to verify the accuracy of the information obtained pursuant to clause ii ; above; v ; The Optionee is aware that the Company shall place stop transfer orders with its transfer agent against the transfer of the Option Shares in the absence of registration under the 1933 Act or an exemption therefrom as provided herein; vi ; The Optionee's rights with respect to the Option Shares shall, in all respects, be subject to the terms and conditions of the Plan and this Agreement; and vii ; Unless the shares delivered upon exercise are registered under the 1933 Act, the certificates evidencing the Option Shares shall bear the following legends: "The shares represented by this certificate have been acquired for investment and have not been registered under the Securities Act of 1933. The shares may not be sold or transferred in the absence of such registration or an exemption therefrom under said Act, because nihfi.

Make sure doctors and other health care providers know your medication allergies. Make sure you can read the prescription your doctor writes before leaving the doctor's office. Talk to a nurse or a pharmacist. They also can help you get a treatment plan that is right for you. Bring a friend or family member with you when you visit your doctor. Remember: Your medicine was prescribed for you. Never share your prescription medicines with anyone and lamotrigine, for example, drug interactions. Total OTC Market: FFr 40.5 billion retail prices ; According to the OTC industry association, the AFIPA, the top seven products on the self-medication market are all analgesics Doliprane, Efferalgan, Efferalgan Vitamin C, Nurofen, Aspirine Vitamin C Upsa, Aspgic, Dafalgan ; . The AFIPA notes that the self medication market appears to be declining with sales of the five main product groups which account for three-quarters of the market by volume and 65%-70% by value ; all falling in 2000. Sales of respiratory tract medications, digestive tract medications and vitamin and mineral supplements all fell in value by around 10%, whilst sales of analgesics and dermatologicals registered a 2%3% decline. One obstacle to the development of the self medication market is the fact that non-reimbursable OTC products tend to have much higher prices than semi-ethicals, with product prices increasing by 20% to 30% when they switch from semi-ethical to full OTC status. The price difference is further widened by the fact that VAT is levied at 2.1% on semi-ethicals and 5.5% on OTC products. It had been expected that the self-medication market would benefit from the government's recent review of reimbursable products, as those drugs given an insufficient medical value rating risk losing their reimbursable status. However, in the short term at least, the government has opted for a series of price cuts, rather than delisting, as most of the products in question vein tonics and other circulatory products, dietary supplements ; are primarily sold by French manufacturers and for the smaller firms these products can represent a sizeable proportion of revenues and profits45. There is a feeling that the government may try to cut prices to the extent where companies themselves decide to switch them to OTC status. Recently, CEPS has been granting companies higher prices for their prescription products in exchange for semi-ethicals switching to OTC status. The overall impact on sales of non-prescription products as a result of any widespread delisting of semi-ethicals is difficult to judge. This is because many of the older non-essential products such as vein tonics and dietary supplements are less likely to be purchased once people have to pay full price for them, particularly as their medical efficacy will have been called into question. However, sales in other categories such as analgesics, antacids and cough and cold remedies should be less affected, and some companies have already opted to have products delisted so that they can freely advertise them to the public. Recent examples of product delistings initiated by the manufacturer include Aventis' antacid Maalox, and Sanofi-Synthlabo's analgesic Aspgic, which follows the OTC route of the company's cold remedy Rhinathiol. The top ten players in the self medication market account for nearly 50% of sales46 with individual market share ranging from 3% to 7%. Four are French-owned Pierre Fabre, Sanofi-Synthlabo, Arkopharma and Boiron ; and the other six are subsidiaries of multinationals Thraplix Aventis, Upsa BMS, Roche Nicholas Roche, GSK Sant Grand Public GSK, Warner-Lambert Pfizer, Lipha Merck.
Unethical conduct exists in science, as in any profession, but scientists running a study or lab can take several steps to prevent or identify research misconduct in an effective way, according to a presentation at an ethics workshop in conjunction with ENDO 2005. The presentation, authored by Peter Abbrecht, M.D., Ph.D., of the U.S. government's Office of Research Integrity, listed the following 12 guidelines to help prevent misconduct: Establish a lab climate that stresses the need and reasons for scientific integrity. Thoroughly train all staff in integrity principles and in conducting their portions of the protocol. Maintain strong communication between supervisors and staff, and ensure a supervising "presence" in the study setting, such as verifying a sample of the research records. Require that any data forms are altered by strike-through, rather than eliminating the original. Changes should have initials and date. Question staff about data alterations in the research record and levothyroxine. Phosphatase activity of the kidney P 0.05 ; Table 1 ; , which was followed three days later by a significant increase in enzyme activity P 0.05 ; resulting to about 36% increase by the end of the experimental period Table 1 ; . These increases in the tissues were not reflected in the serum as there was no significant change in serum alkaline phosphatase activity throughout the duration of experiment P 0.05 ; Table 1 ; . Table 2 depicts the activities of acid phosphatase during the same period. There was significant reduction P 0.05 ; in liver acid phosphatase activities throughout the period of administration. There was however a significant increase P 0.05 ; in kidney acid phosphatase activities during the same experimental period. On the contrary, serum acid phosphatase activities did not manifest any significant change P 0.05 ; when compared with the control values.
Drug ketotifen or report drowsiness, to minimize 2 several unusual medication during in if slowly very crush pharmacist and lithobid. N 1981, a new professional group, the American Pain Society APS ; , was formed to understand and treat pain.And although patients still hurt today, there has been progress: The science and understanding of pain has evolved.The Cytochrome P450 CYP450 ; system is no longer a curiosity in biochemistry and intracellular physiology lectures.Among other uses, it has become the basis for understanding drug-drug interactions and explaining medication toxicity in special populations, and among those that must rely on rational polypharmacy. So we know more. But we cannot always prescribe more. Over the past 10 years, the pendulum has swung back and forth between prescribe-nothing-forpain to prescribe everything. Without clear guidance from one consistent central authority read: DEA ; , physicians live in an "Alice in Wonderland" reality where one group demands better pain management while another threatens prosecution for being overzealous. Physicians worry that they could pay huge fines for coding errors, suffer incarceration for good medical judgement or, if they are "lucky, " face only malpractice suits. Is it any surprise that there is a national shortage of pain practitioners? Or that millions of Americans languish in pain without help? Our recourse is to ride the swinging penduB. Eliot Cole, MD, lum until it stops.And keep is the executive screening for substance director of the American Society abuse, although genetic of Pain Educators markers aren't absolutely reliable.